BooHackLab

Author: Sunny Dhillon BPharm, MBA

While antioxidants protect cells from damage and NAD+ fuels their repair, a third challenge remains: what happens to cells that have accumulated too much damage to function properly yet refuse to die? These senescent cells, sometimes called "zombie cells," represent one of the most studied targets in contemporary longevity research. Compounds that selectively eliminate senescent cells, commonly referred to as senolytics, have generated significant interest in preclinical research and early clinical studies.

Senolytic supplements contain compounds designed to selectively clear senescent cells that accumulate with age and release inflammatory signals. The field is still early; while preclinical results have been compelling in model systems, human evidence remains preliminary and ongoing clinical trials are testing safety, dosing, and efficacy.

Understanding Cellular Senescence

Cellular senescence initially serves a protective function by stopping damaged cells from dividing. This prevents potentially cancerous mutations from spreading. Problems arise when these cells accumulate over decades, releasing inflammatory molecules known as the senescence-associated secretory phenotype (SASP).

According to research from the Mayo Clinic, SASP includes pro-inflammatory cytokines, matrix-degrading enzymes, and growth factors that disrupt surrounding tissue.1 SASP factors can induce senescence in neighbouring healthy cells, spreading dysfunction throughout tissues. Senolytic compounds work by selectively triggering cell death in senescent cells while sparing healthy ones.

Fisetin: The Most Potent Natural Senolytic

The landmark Yousefzadeh et al. (2018) study in EBioMedicine compared ten flavonoids for senolytic activity and identified fisetin as a leading candidate in the models tested². In those specific mouse models, intermittent fisetin treatment improved several healthspan measures and produced modest increases in median and maximum lifespan; results varied by strain and experimental conditions. This effect was observed when treatment began in older animals in the reported studies, indicating potential benefit in late‑life interventions in those models.

The AFFIRM-LITE trial (NCT03675724) at Mayo Clinic is currently investigating fisetin in humans aged 70-90. Additionally, Mahoney et al. (2024) in Aging Cell demonstrated that intermittent fisetin supplementation improved arterial function in old mice by decreasing cellular senescence.3

Preclinical mouse studies have used intermittent ‘hit‑and‑run’ regimens (for example, short courses such as 20 mg/kg for 2–3 consecutive days in specific mouse models) to achieve senolytic effects; these animal regimens are not directly translatable to humans and should not be used to infer human dosing.2

Quercetin: Context and Caveats

The most widely cited clinical senolytic regimen to date is dasatinib plus quercetin (D+Q); evidence for senolytic effects in humans primarily involves this combination rather than quercetin monotherapy. Hickson et al. (2019) reported reductions in senescent cell markers in a small, early clinical study of D+Q in individuals with diabetic kidney disease, providing preliminary human evidence for the senolytic concept.4

Importantly, quercetin alone has not been proven senolytic in adult human cells. It does, however, provide established anti-inflammatory and antioxidant benefits that support cellular health through complementary mechanisms. Standard quercetin has poor absorption, though Liu et al. (2025) in Food Chemistry showed that enhanced formulations can improve bioavailability up to 62-fold.5

Spermidine: The Autophagy Activator

Unlike direct senolytics, spermidine supports cellular health through autophagy activation, the cellular recycling process that clears damaged components. Autophagy is one of the body's primary maintenance mechanisms, breaking down and recycling damaged proteins and organelles to maintain cellular function.

Hofer et al. (2024) in Nature Cell Biology established spermidine as an obligatory downstream effector of fasting benefits.6This means that some of the cellular benefits attributed to fasting may actually be mediated through spermidine's effects on autophagy.

The SmartAge Trial by Schwarz et al. (2022) in JAMA Network Open found no significant cognitive benefit at 0.9 mg daily, though this dose may have been insufficient.7Higher doses up to 40 mg daily have proven safe in subsequent research. Eisenberg et al. (2009) in Nature Cell Biology demonstrated that spermidine induces autophagy and promotes longevity in model organisms.8

Expert Perspective and Caution

Dr. James Kirkland, a senolytic research pioneer, has publicly cautioned: "People have to be very, very concerned about what they buy. We know 2% of what we need to know. This is a completely new area of medicine." This perspective underscores that while senolytic research is exciting, it remains in its early stages for human application.

Honest perspective is essential. Evidence is strongest for the concept of senolytic therapy, with human trials now validating the approach. However, optimal dosing, timing, and compound selection for over-the-counter senolytic supplements remain areas of active investigation.

How Oral Film Strips (OFSs) enable rapid onset and enhanced absorption 

Many senolytic compounds face significant bioavailability challenges. Flavonoids like fisetin and quercetin have poor membrane permeability when taken orally as a capsule, tablet or powder, with much of the compound passing through the GI tract unabsorbed. 

Oral Film Strips (OFSs) have emerged as a modern drug-delivery platform offering distinct biopharmaceutical advantages over conventional tablets. Their ultra-thin polymeric matrices rapidly disintegrate upon contact with saliva, enabling immediate drug release and exposure to the highly vascularised buccal and sublingual mucosa, which supports rapid absorption and the potential avoidance of first-pass metabolism.9,10

Numerous reviews highlight that this pre-gastric uptake can enhance systemic bioavailability, particularly for drugs with poor solubility, extensive first-pass metabolism, or slow disintegration from tablets.11,12

OFSs also allow incorporation of permeation enhancers, solubilising agents, and mucoadhesive polymers, which increase mucosal residence time and improve transmucosal flux, further supporting superior absorption profiles compared with traditional solid oral dosage forms.13,14,15

Collectively, the literature positions OFSs as an innovative and patient-centric dosage form capable of delivering faster onset, improved absorption efficiency, and potentially higher effective bioavailability relative to standard tablets.16

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare provider before beginning any supplement regimen.

Frequently Asked Questions

What are senolytic supplements and should I take them?

Senolytic supplements contain compounds designed to selectively clear senescent cells, the dysfunctional "zombie cells" that accumulate with age and release inflammatory signals. Fisetin and quercetin are natural compounds showing senolytic properties in preclinical research. Human evidence remains early: the dasatinib plus quercetin combination has demonstrated effects in clinical trials, while fisetin trials are ongoing at Mayo Clinic. Experts advise caution as this field is new. 

How do senolytics differ from antioxidants and NAD+ supplements?

Each targets a different hallmark of aging. Antioxidants like glutathione and vitamin C neutralize reactive oxygen species to prevent oxidative damage. NAD+ precursors like NMN restore the cellular fuel needed for energy production and DNA repair. Senolytics take a different approach entirely by selectively clearing cells that have become dysfunctional and inflammatory. These three strategies are complementary, addressing cellular aging from reactive, proactive, and restorative angles.

References

1. Xu, M., et al. (2018). Senolytics improve physical function and increase lifespan in old age. Nature Medicine, 24(8), 1246-1256. https://doi.org/10.1038/s41591-018-0092-9

2. Yousefzadeh, M. J., et al. (2018). Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine, 36, 18-28. https://doi.org/10.1016/j.ebiom.2018.09.015

3. Mahoney, S. A., et al. (2024). Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence. Aging Cell, 23(3), e14060. https://doi.org/10.1111/acel.14060

4. Hickson, L. J., et al. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine, 47, 446-456. https://doi.org/10.1016/j.ebiom.2019.08.069

5. Liu, L., et al. (2025). Bioavailability enhancement strategies for quercetin: A systematic review and meta-analysis of human studies. Food Chemistry, 477, 143630. https://doi.org/10.1016/j.foodchem.2024.143630

6. Hofer, S. J., et al. (2024). Spermidine-induced hypusination preserves mitochondrial and cognitive function during aging. Nature Cell Biology, 26, 386-399. https://doi.org/10.1038/s41556-024-01468-x

7. Schwarz, C., et al. (2022). Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline: A randomized clinical trial. JAMA Network Open, 5(5), e2213875. https://doi.org/10.1001/jamanetworkopen.2022.13875

8. Eisenberg, T., et al. (2009). Induction of autophagy by spermidine promotes longevity. Nature Cell Biology, 11(11), 1305-1314. https://doi.org/10.1038/ncb1975

9. Patil, P., & Shrivastava, S. K. (2014). Fast dissolving oral films: An innovative drug delivery system. International Journal of Science and Research, 3(7), 2088–2093. [

10. Özakar, R. S., & Özakar, E. (2021). A current overview of oral thin films. Turkish Journal of Pharmaceutical Sciences, 18(1), 111–121.  

11. Paul, D., & Ray, P. (2023). Exploring the potential of fast dissolving oral films. Current Trends in Pharmaceutical Research, 10

12. He, M., Zhu, L., Yang, N., Li, H., & Yang, Q. (2021). Recent advances of oral film as a platform for drug delivery. International Journal of Pharmaceutics, 604, Article 120759. https://doi.org/10.1016/j.ijpharm.2021.120759

13. Sharma, D., Kaur, D., Verma, S., Verma, S., Singh, M., & Garg, R. (2015). Fast dissolving oral films technology: A recent trend for an innovative oral drug delivery system. International Journal of Drug Delivery, 7(2), 

14. Bhaijamal, R. A., Virabhai, M. Y., Maisuriya, A. B., & Kachhiya, S. K. (2025). Comparative evaluation of fast dissolving films vs conventional oral dosage forms of antihistamine in terms of drug dissolution. International Journal of Innovative Research & Growth, 14(2), 14240–14258.  

15. Devaraj, H., Venkatachalam, S., & Radhakrishnan, A. (2018). A review on formulation of oral dissolving film. Journal of Chemical and Pharmaceutical Research, 10(4), 151–159. 

16. Dhankar, K., Tamrakar, H. K., Deshmukh, S., Wadhwa, G. S., Toppo, M. A., Jaya Shree, & Choudhary, R. (2025). Oral fast dissolving film: Pharmaceutical development and approaches. International Journal of Pharmaceutical Research and Development, 7(2), 04–12.